REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO (Nasdaq: RGNX) reported long-term follow-up data for investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD and diabetic retinopathy at ASRS. Wet AMD results showed stable or improved vision through 5 years and reduced anti-VEGF injections, with no new intraocular inflammation. DR data showed 55% >2-step DRSS improvement at 2.5 years. Pivotal topline data with AbbVie expected Q4 2026.
How this was made
The 30-second read
Why it matters
The new long-term follow-up data are designed to support durability and safety, potentially improving probability-weighting for later-stage success ahead of Q4 2026 pivotal toplines.
Market read
Traders may reprice sura-vec’s durability/safety profile, but the decisive catalyst remains the Q4 2026 pivotal topline results.
What to watch
The article highlights no new IOI but does not quantify effect sizes versus anti-VEGF in pivotal settings, and the wet AMD discussion includes a polypoidal participant exception that may not generalize.
Background
REGENXBIO’s sura-vec (ABBV-RGX-314) is an investigational one-time gene therapy targeting VEGF via AAV8 vector delivery, evaluated in wet AMD (subretinal) and diabetic retinopathy (suprachoroidal).
Ticker impact
REGENXBIO reported 5-year wet AMD and 2.5-year DR long-term follow-up for sura-vec, with no new intraocular inflammation signals.
Potentially supportive near-term sentiment, but likely capped until Q4 2026 ATMOSPHERE and ASCENT topline data.
The article is a new long-term dataset presented at ASRS, but it does not provide the pivotal primary endpoint results or new regulatory/financing catalysts.
Market effects
Reinforces investor appetite for one-time gene therapy approaches in retinal disease, potentially improving sentiment for AAV gene therapy peers.
Limited direct regional impact; primarily US biotech sentiment.
Wet AMD and diabetic retinopathy are global markets, so durable data can influence international biotech sentiment around retinal gene therapy.
Counterpoint
Long-term follow-up in earlier-stage cohorts may not translate to pivotal trial primary endpoints, so the market may discount durability claims until ATMOSPHERE and ASCENT topline.
Key entities
- companyREGENXBIO Inc.
Nasdaq-listed biotech presenting long-term sura-vec data for wet AMD and diabetic retinopathy.
- productsura-vec (ABBV-RGX-314)
Investigational one-time gene therapy for VEGF inhibition in retinal diseases.
- partnerAbbVie
Collaborator referenced for Q4 2026 topline data from ATMOSPHERE and ASCENT.
